Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age

Summary

This study will be investigating the safety and efficacy of Xyntha (moroctocog alfa (AF-CC)) in male patients less than 6 years old. Annualized bleeding rates and physician / caregiver assessments of responses to treatment will be characterized. FVIII inhibitor levels will be assessed throughout the study.

Timeline

Start

2009-06

Primary completion

2009-12

Completion

2009-12

Drugs

Indications